Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II CIS regimen (cetuximab + irinotecan + sunitinib) in treatment-resistant colorectal cancer
2007-004232-22Phase 2Completed
- Sponsor
- University Hospital Odense
- Start
- Oct 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab, irinotecan, sunitinib in colorectal cancer (CRC), sponsored by University Hospital Odense. Started Oct 2007; status: completed.
02
Drugs
cetuximabirinotecansunitinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2007-004232-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004232-22.